FDA Cross-Center Collaboration Act of 2016

House Bill 5414 - FDA Cross-Center Collaboration Act of 2016: Overview, Status, and Impact

Hozzl · 2023-01-11T13:32:49Z

Explore the details of House Bill 5414 FDA Cross-Center Collaboration Act of 2016 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

1/11/2023, 1:32 PM

Congressional Summary of HR 5414

FDA Cross-Center Collaboration Act of 2016

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish one or more Intercenter Institutes. Each institute must coordinate activities applicable to a major disease area among the FDA centers that review products. Activities may include coordinating staff with relevant expertise, streamlining product review, and enhancing interactions with patients, sponsors, and the biomedical community.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 5414

Bill HR 5414 is currently in the status of Bill Introduced since June 8, 2016. Bill HR 5414 was introduced during Congress 114 and was introduced to the House on June 8, 2016. Bill HR 5414's most recent activity was Referred to the House Committee on Energy and Commerce. as of June 8, 2016

Bipartisan Support of Bill HR 5414

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 5414

Primary Policy Focus

Health

Potential Impact Areas

- Department of Health and Human Services

- Drug safety, medical device, and laboratory regulation

- Executive agency funding and structure

- Food and Drug Administration (FDA)

- Government employee pay, benefits, personnel management

- Health promotion and preventive care

- Medical education

Alternate Title(s) of Bill HR 5414

FDA Cross-Center Collaboration Act of 2016

To amend the Federal Food, Drug, and Cosmetic Act to provide for establishment of one or more Intercenter Institutes within the Food and Drug Administration for a major disease area or areas, and for other purposes.

FDA Cross-Center Collaboration Act of 2016